

# **Pillar 3 Regulatory Capital Disclosures** Truist Financial Corporation June 30, 2022

## **Table of Contents**

	Page No.
Glossary of Defined Terms	<u>1</u>
Introduction	<u>3</u>
Capital Structure	<u>3</u>
Capital Adequacy Process	<u>8</u>
Credit Risk	<u>9</u>
Credit Risk Mitigation	<u>17</u>
Securitizations	<u>18</u>
Equity Securities Not Subject to Market Risk Rule	<u>20</u>
Appendix:	
Cross Reference Table	<u>22</u>
Forward-Looking Statements	<u>29</u>

## **Glossary of Defined Terms**

Allowance for credit losses
Acquisition and development and commercial land
Available-for-sale
Mortgage-backed securities issued by a U.S. government agency or GSE
Allowance for loan and lease losses
Accumulated other comprehensive income (loss)
Bank-owned life insurance
Rules issued by the FRB, OCC, and FDIC on capital adequacy and liquidity requirements in the U.S for banking organizations.
BB&T Corporation and subsidiaries (changed to "Truist Financial Corporation" effective with the Merger)
Basel Committee on Banking Supervision
Bank holding company
Capital Adequacy Process
The Coronavirus Aid, Relief, and Economic Security Act
Comprehensive Capital Analysis and Review
Central clearing party
Certificate of deposit
Credit default swaps
Current expected credit loss
Credit-enhancing interest-only strip
Common equity tier 1
Truist Financial Corporation and subsidiaries (interchangeable with "Truist" below)
Coronavirus disease 2019
Construction and permanent
Community Reinvestment Act of 1977
Commercial real estate
Credit uplustice adjustment
Credit valuation adjustment
Dodd-Frank Wall Street Reform and Consumer Protection Act
Debit valuation adjustment
Federal Deposit Insurance Corporation
Federal Financial Institutions Examination Council
Financial Holding Company
Board of Governors of the Federal Reserve System
Accounting principles generally accepted in the United States of America
U.S. government-sponsored enterprise
Held-to-maturity
High volatility commercial real estate
International Swaps and Derivatives Association, Inc.
Liquidity Coverage Ratio
Loans and leases held for investment
Loans held for sale
London Interbank Offered Rate
Mortgage-backed securities
Management's Discussion and Analysis
Multilateral development bank
Merger of BB&T and SunTrust effective December 6, 2019
North Carolina Office of the Commissioner of Banks
Nonperforming asset
Net stable funding ratio
Office of the Comptroller of the Currency
Over-the-counter
Truist Financial Corporation, the parent company of Truist Bank and other subsidiaries

Term	Definition
PPP	Paycheck Protection Program
PSE	Public sector entity
Rule	Basel III Final Rule
RWA	Risk-weighted assets
SCB	Stress Capital Buffer
SEC	Securities and Exchange Commission
SPE	Special purpose entity
SunTrust	SunTrust Banks, Inc.
SSFA	Simplified Supervisory Formula Approach
Tailoring Rules	Final rules changing the applicability thresholds for regulatory capital and liquidity requirements, issued by the OCC, FRB, and FDIC, together with the final rules changing the applicability thresholds for enhanced prudential standards issued by the FRB
TDR	Troubled debt restructuring
Truist	Truist Financial Corporation and subsidiaries
Truist Bank	Truist Bank
U.S.	United States of America
U.S. Treasury	United States Department of the Treasury

## Introduction

Truist is a FHC and conducts its business operations through its bank subsidiary, Truist Bank, and other non-bank subsidiaries. Truist is a purpose-driven financial services company committed to inspiring and building better lives and communities. Truist has leading market share in many high-growth markets in the country. The Company offers a wide range of services including retail, small business and commercial banking; asset management; capital markets; commercial real estate; corporate and institutional banking; insurance; mortgage; payments; specialized lending; and wealth management. Headquartered in Charlotte, North Carolina, Truist is a top 10 U.S. commercial bank.

Truist Bank is a state non-member bank and is supervised by the FDIC and NCCOB, while Truist is supervised by the FRB. Truist's nonbank subsidiaries are regulated and supervised by various other regulatory bodies, including the Securities and Exchange Commission and the Financial Industry Regulatory Authority.

This report provides information about Truist's capital structure, capital adequacy, risk exposures, RWA, and risk management framework. It should be read in conjunction with Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended June 30, 2022 and the Consolidated Financial Statements for Bank Holding Companies - Form FR Y-9C for the period ended June 30, 2022. Truist's SEC filings are located on its website at <u>ir.truist.com/sec-filings</u>.

## Pillar 3 Report Overview

The Basel framework consists of a three "Pillar" approach:

- Pillar 1 establishes minimum capital requirements, defines eligible capital instruments, and prescribes rules for calculating RWA.
- Pillar 2 requires banks to have an internal capital adequacy assessment process and requires that banking supervisors evaluate each bank's overall risk profile as well as its risk management and internal control processes.
- Pillar 3 encourages market discipline through disclosure requirements which allow market participants to assess the risk and capital profiles of banks.

The cross reference table located in the Appendix specifies the location of disclosures required by the Rule.

#### Basis of Consolidation

The basis of consolidation used for regulatory reporting is the same as that used under GAAP. The disclosures contained herein are on a consolidated basis unless otherwise noted. There are no entities within Truist that are deconsolidated for regulatory reporting, or whose capital is deducted. These disclosures have not been audited by the Company's external auditors.

See "Principles of Consolidation" in "Note 1. Basis of Presentation" in Truist's June 30, 2022 Form 10-Q for more information on the basis of consolidation.

## **Capital Structure**

Truist and Truist Bank are subject to certain risk-based capital and leverage ratio requirements established by the FRB, for Truist, and by the FDIC, for Truist Bank. These requirements are based on the capital framework developed by the BCBS for strengthening the regulation, supervision, and risk management of banks under Basel III rules, as well as certain provisions of the Dodd-Frank Act. These quantitative calculations are minimums, and the FRB and FDIC may determine that a banking organization, based on its size, complexity, or risk profile, must maintain a higher level of capital in order to operate in a safe and sound manner. Failure to be well capitalized or to meet minimum capital requirements could result in certain mandatory and possible additional discretionary actions by regulators that, if undertaken, could have an adverse material effect on Truist's operations or financial condition. These actions could include requiring Truist commit capital to Truist Bank in abnormal operating conditions which would otherwise be available to Truist's or Truist's or Truist Bank's ability to pay dividends or otherwise distribute capital or to receive regulatory approval for acquisitions.

As of June 30, 2022, Truist and Truist Bank qualified as well capitalized, with capital levels in excess of the minimum regulatory capital requirements.

## **Definition of Capital**

Regulatory capital includes the following elements:

- CET1 capital includes primarily common shareholders' equity subject to certain regulatory adjustments and deductions, which
  excludes the impact of goodwill, intangible assets, certain deferred tax assets, AOCI, and the impact of the CECL transition
  provision.
- Tier 1 capital includes primarily CET1 capital, perpetual preferred stock, and certain qualifying capital instruments.
- Tier 2 capital includes primarily qualifying subordinated debt and qualifying ACL. Tier 2 capital also includes, among other things, certain trust preferred securities.
- Total capital includes Tier 1 capital plus Tier 2 capital.

A reconciliation of total shareholders' equity to CET1 capital, Tier 1 capital, Tier 2 capital, and Total capital is presented in Truist's June 30, 2022 Form FR Y-9C. Refer to the "Consolidated Balance Sheets" in Truist's June 30, 2022 Form 10-Q for the components of total shareholders' equity.

## Capital in Subsidiaries

At June 30, 2022, the amount of surplus capital of insurance subsidiaries included in regulatory capital was not material.

## RWA

Under the Rule, Truist's and Truist Bank's assets, exposures, and certain off-balance sheet items are subject to risk weights used to determine the institutions' RWA. These RWA are used to calculate the required minimum capital ratios for Truist and Truist Bank. See the "Capital Ratios" section herein for further discussion of the capital ratio components.

The RWA calculation is used in determining the institution's capital requirement. RWA under the standardized approach are generally based on supervisory risk weightings that vary by counterparty type and asset class. The predefined risk weight classifications generally range from 0% for U.S. government securities to 600% for certain equity exposures, with a maximum risk weight classification of 1,250% for certain securitization exposures.

## Market Risk Rule

Certain large banking organizations with trading assets and liabilities above certain thresholds, including Truist, are subject to the Market Risk Rule and must adjust their risk-based capital ratios to reflect the market risk of their trading activities. Refer to the "Market Risk" section in the MD&A of the Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended June 30, 2022 for additional disclosures related to market risk management.

#### Components of RWA

The following table presents Truist's RWA by exposure type at June 30, 2022:

Table 3-1 Basel III Standardized Transitional Approach RWA

(dollars in millions)	June 30, 2022
Credit risk (1):	
Corporate and consumer exposures (2)	\$ 315,255
Exposure to residential mortgage loans	41,897
Exposure to GSEs	18,403
Equity exposures	14,527
Exposure to PSEs	5,817
Securitization exposures	3,488
Exposure to OTC derivatives	2,626
Exposure to HVCRE loans	1,938
Exposure to sovereign entities	1,668
Exposure to depository institutions, foreign banks and credit unions	1,219
Exposure to past due loans	1,124
Exposure to statutory multifamily mortgage	1,005
Unsettled transactions	9
Cleared transactions	8
Total standardized credit risk	408,984
Total standardized market risk	4,400
Total standardized RWA	\$ 413,384

(1) Truist does not have any exposures to supranational entities and MDBs or default fund contributions.

(2) Corporate and consumer exposures also include other assets.

See the Company's June 30, 2022 Form Y-9C, Schedule HC-R Part I and Part II, on the FFIEC website for disclosures required by Basel III related to the following:

- Total standardized RWA by exposure type, including the related on- and off-balance sheet exposure;
- Standardized market RWA as calculated under the Market Risk Rule. Additional details are also available in the FFIEC 102 report on the FFIEC's website; and
- CET1, Tier 1 capital, and Total risk-based capital components and related calculations.

#### **Capital Ratios**

Under capital adequacy guidelines and the regulatory framework for prompt corrective action, the Company must meet specific capital guidelines that involve quantitative measures of assets, liabilities, and certain off-balance sheet items calculated pursuant to regulatory directives. Truist's capital amounts and classifications are also subject to qualitative judgments by the regulators about components, risk weightings, and other factors. Truist is in full compliance with these requirements. Banking regulations also identify five capital categories for insured depository institutions: well capitalized, adequately capitalized, undercapitalized, significantly undercapitalized, and critically undercapitalized. At June 30, 2022, Truist and Truist Bank were classified as "well capitalized," and management believes that no events or changes have occurred subsequent to period end that would change this designation.

To avoid certain regulatory restrictions, Truist and Truist Bank are required to maintain minimum ratios of CET1 ratio of 4.5%, Tier 1 capital ratio of 6%, Total capital to risk-weighted assets ratio of 8%, Tier 1 capital to quarterly average tangible assets (leverage ratio) of 4%, and Tier 1 capital to total exposures (supplementary leverage) of 3%.

#### Capital conservation buffer and Stress Capital Buffer

Truist and Truist Bank are subject to certain risk-based capital and leverage ratio requirements established by the FRB, for Truist, and by the FDIC, for Truist Bank. These requirements are based on the capital framework developed by the BCBS for strengthening the regulation, supervision, and risk management of banks under Basel III rules, as well as certain provisions of the Dodd-Frank Act. These quantitative calculations are minimums, and the FRB and FDIC may determine that a banking organization, based on its size, complexity, or risk profile, must maintain a higher level of capital in order to operate in a safe and sound manner. Failure to be well capitalized or to meet minimum capital requirements could result in certain mandatory and discretionary actions by regulators that, if undertaken, could have an adverse material effect on Truist's operations or financial condition. These actions could include requiring Truist commit capital to Truist Bank in abnormal operating conditions which would otherwise be available to Truist's or Truist Bank's ability to pay dividends or otherwise distribute capital or to receive regulatory approval for acquisitions.

Truist's SCB is equal to the greater of (i) the difference between its starting and minimum projected CET1 capital ratios under the severely adverse scenario in the supervisory stress test, plus the sum of the dollar amount of its planned common stock dividends for each of the fourth through seventh quarters of the planning horizon as a percentage of risk-weighted assets, or (ii) 2.5%. The FRB assigned Truist an SCB of 2.5%, which is effective from October 1, 2021 through September 30, 2022. Truist completed the 2022 CCAR process and received the preliminary SCB requirement of 2.5% for the period October 1, 2022 to September 30, 2023. Truist had the second-lowest CET1 erosion and loan loss rate among its peers under the severely adverse stress scenario. By August 31, 2022, the FRB will provide Truist with its final SCB requirement. Although the final rule continues to require that the firm describe its planned capital distributions in its CCAR capital plan, Truist is no longer required to seek prior approval if it makes capital distributions in excess of those included in its CCAR capital plan. Instead, Truist is subject to automatic distribution limitations if its capital ratios fall below its buffer requirements, which include the SCB.

For certain large banking organizations, the SCB could be supplemented by a countercyclical capital buffer of up to an additional 2.5% of risk-weighted assets. This buffer is currently set at zero. An FRB policy statement establishes the framework and factors the FRB would use in setting and adjusting the amount of the countercyclical capital buffer. Covered banking organizations would generally have 12 months after the announcement of any increase in the countercyclical capital buffer to meet the increased buffer requirement, unless the FRB establishes an earlier effective date. If the full countercyclical buffer amount is implemented, Truist and Truist Bank would be required to maintain a CET1 capital ratio of at least 9.5%, a Tier 1 capital ratio of at least 11.0%, and a Total capital ratio of at least 13.0% to avoid limitations on capital distributions and certain discretionary incentive compensation payments. See additional discussion related to the capital conservation buffer and SCB in Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended June 30, 2022.

Truist and Truist Bank are subject to a Tier 1 leverage ratio, equal to the ratio of Tier 1 capital to quarterly average assets, net of goodwill, certain other intangible assets, and certain other deductions. Category III banking organizations are also subject to a minimum 3.0% supplementary leverage ratio. The supplementary leverage ratio is calculated by dividing Tier 1 capital by total leverage exposure, which takes into account on-balance sheet assets as well as certain off-balance sheet items, including loan commitments and potential future exposure of derivative contracts.

The total minimum regulatory capital ratios and well capitalized minimum ratios applicable to Category III banking organizations at June 30, 2022 are reflected in the table below. The FRB has not yet revised the well capitalized standard for BHCs to reflect the higher capital requirements imposed under the Basel III Rules. For purposes of certain FRB rules, including determining whether a BHC meets the requirements to be a FHC, BHCs, such as Truist, must maintain a Tier 1 Risk-Based Capital Ratio of 6.0% or greater and a Total Risk-Based Capital Ratio of 10.0% or greater. The FRB may require BHCs, including Truist, to maintain capital ratios substantially in excess of mandated minimum levels, depending upon general economic conditions and a BHC's particular condition, risk profile, and growth plans.

## Table 3-2 Capital Requirements June 30, 2022

	_	Well Capi	italized	Minimum Capital Plus Stress
CET1 Tier 1 capital Total capital Leverage ratio Supplementary leverage ratio	Minimum Capital	Truist	Truist Bank	Capital Buffer (1)
CET1	4.5 %	NA	6.5 %	7.0 %
Tier 1 capital	6.0	6.0 %	8.0	8.5
Total capital	8.0	10.0	10.0	10.5
Leverage ratio	4.0	NA	5.0	NA
Supplementary leverage ratio	3.0	NA	NA	NA

(1) Reflects a SCB of 2.5% applicable to Truist as of June 30, 2022. Truist's SCB, received in the 2021 CCAR process, is effective from October 1, 2021 to September 30, 2022. Under the 2022 CCAR process, Truist was notified its preliminary SCB requirement would remain 2.5% from October 1, 2022 through September 30, 2023.

For additional information refer to "Item 1. Business" section and the "Capital" MD&A section in Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and the "Capital" MD&A section in Truist's Quarterly Report on Form 10-Q for the period ended June 30, 2022.

The following table presents regulatory capital and risk-based capital ratios for Truist and Truist Bank at June 30, 2022:

Table 3-3 Capital Ratios June 30, 2022

(dollars in millions)	Ratio	Amount
Truist:		
CET1	9.2 % \$	38,016
Tier 1 capital	10.8	44,686
Total capital	12.6	52,186
Leverage	8.6	44,686
Supplementary leverage ratio	7.3	44,686
Truist Bank:		
CET1	9.9 % \$	40,040
Tier 1 capital	9.9	40,040
Total capital	11.4	45,909
Leverage	7.9	40,040
Supplementary leverage ratio	6.7	40,040

## Other Capital Ratio Considerations

## Revisions to Definition of Eligible Retained Income

The U.S. banking agencies have adopted a final rule altering the definition of eligible retained income. Under the final rule, eligible retained income is the greater of a firm's (i) net income for the four preceding calendar quarters, net of any distributions and associated tax effects not already reflected in net income, and (ii) average net income over the preceding four quarters. This definition applies with respect to all of Truist's capital requirements.

#### Current Expected Credit Losses Methodology

In 2020, the U.S. banking agencies adopted a final rule that permits banking organizations that implemented CECL before the end of 2020 to elect to follow the three-year transition available under the prior rule or a new five-year transition to phase in the effects of CECL on regulatory capital. Under the five-year transition, the banking organization would defer for two years 100% of the day-one effect of adopting CECL and 25% of the cumulative increase or decrease in the allowance for credit losses since adoption of CECL. Following the first two years, the electing organization will phase out the aggregate capital effects over the next three years consistent with the transition in the original three-year transition rule. Truist has elected to use the five-year transition to phase in the impacts of CECL on regulatory capital. The 2022 impact on CET1 related to the phase in was 13 basis points, representing one-fourth of the phase in. The remaining phase in will be amortized ratably in the first quarter of each of the next three years.

## **Capital Adequacy Process**

The maintenance of appropriate levels of capital is a top priority of management and is monitored on a regular basis. Truist's principal goals related to the maintenance of capital are to provide adequate capital to support Truist's risk profile consistent with its Board-approved risk appetite, provide financial flexibility to support future growth and client needs, comply with relevant laws, regulations, and supervisory guidance, achieve optimal credit ratings for Truist and its subsidiaries, and provide a competitive return to shareholders.

## Enhanced Prudential Standards and Regulatory Tailoring Rules

Certain U.S. BHCs, including Truist, are subject to enhanced prudential standards. As such, Truist is subject to more stringent liquidity and capital requirements, leverage limits, stress testing, resolution planning and risk management standards than those applicable to smaller institutions. Truist is subject to the FRB's single-counterparty credit limit rule and is also subject to a limit of 25% of Tier 1 capital for aggregate net credit exposures, including exposure resulting from, among other transactions, extensions of credit, repurchase and reverse repurchase transactions, investments in securities and derivative transactions, to any other unaffiliated counterparty.

Under the Tailoring Rules, Truist is subject to the standards applicable to Category III banking organizations, which generally include bank holding companies with greater than \$250 billion, but less than \$700 billion, in total consolidated assets and less than \$75 billion in certain risk-related exposures.

Certain BHCs and their bank subsidiaries, including Truist and Truist Bank, are subject to a minimum LCR. The LCR is designed to ensure that BHCs have sufficient high-quality liquid assets to survive a significant liquidity stress event lasting for 30 calendar days.

Truist also is subject to FRB rules that require certain large BHCs to conduct internal liquidity stress tests over a range of time horizons, maintain a buffer of highly liquid assets sufficient to meet projected net outflows under the BHC's 30-day liquidity stress test, and maintain a contingency funding plan that meets certain requirements.

Effective July 2021, Truist became subject to rules implementing the NSFR, which are designed to ensure that banking organizations maintain a stable, long-term funding profile in relation to their asset composition and off-balance sheet activities. The NSFR, calculated as the ratio of available stable funding to required stable funding, must exceed 1.0x. Available stable funding represents a weighted measure of a company's funding sources over a one-year time horizon, calculated by applying standardized weightings to the company's equity and liabilities based on their expected stability. Required stable funding is calculated by applying standardized weightings to assets, derivatives exposures, and certain other items based on their liquidity characteristics. As a Category III banking organization, Truist and Truist Bank are subject to an NSFR requirement equal to 85% of the full requirement. At June 30, 2022, the Company was compliant with this requirement. Truist's "Liquidity Coverage Ratio Disclosure" are located on its website at <u>ir.truist.com/other-filings</u>.

See Truist's Annual Report on Form 10-K for the year ended December 31, 2021 for a discussion of requirements for Category III banking organizations.

## Capital Planning and Stress Testing Requirements

Truist regularly performs stress testing on its capital levels and is required to periodically submit the Company's capital plans and stress testing results to the banking regulators. Management regularly monitors the capital position of Truist on both a consolidated and bank-level basis. In this regard, management's objective is to maintain capital at levels that are in excess of internal capital targets, which are above the regulatory "well capitalized" minimums. Management has implemented stressed capital ratio minimum targets to evaluate whether capital ratios calculated after the effect of alternative capital actions are likely to remain above minimum specified by the FRB for the annual CCAR process. Breaches of stressed minimum targets prompt a review of the planned capital actions included in Truist's capital plan.

Truist must submit an annual capital plan to the FRB that reflects its projected financial performance under baseline and stressful macroeconomic conditions, and proposed capital distributions must meet SCB requirements based on the FRB's annual CCAR process. Truist generally may pay dividends and interest on capital securities and repurchase or retire capital securities in accordance with a capital plan that meets SCB requirements.

The FRB's CCAR framework and the Dodd-Frank Act stress testing framework also require BHCs subject to Category III standards, such as Truist, to conduct company-run stress tests and submit to supervisory stress tests conducted by the FRB. The company-run stress tests employ stress scenarios provided by the FRB and incorporate the Dodd-Frank Act capital actions, which are intended to normalize capital distribution assumptions across large U.S. BHCs. In addition, Truist is required to conduct annual stress tests using internally-developed scenarios intended to stress the unique risk profile of the institution. The FRB also conducts CCAR and Dodd-Frank Act supervisory stress tests employing internal models on the supervisory stress scenarios. As a Category III banking organization, Truist is subject to supervisory stress testing on an annual basis and company-run stress testing on a biennial basis.

#### **Risk Management**

Truist maintains a comprehensive risk management framework supported by people, processes and systems to identify, measure, monitor, manage, and report significant risks arising from its exposures and business activities. Effective risk management involves appropriately balancing risk and return, operating in a safe and sound manner, and complying with applicable laws and regulations. The Company's risk management framework is designed to ensure that business strategies and objectives are executed in alignment with its risk appetite.

Truist is committed to fostering a culture that supports transparency and escalation of risks across the organization. All teammates are responsible for upholding the Company's purpose, mission, and values, and are encouraged to speak up if there is any activity or behavior that is inconsistent with the Company's culture. The Truist Code of Ethics guides and unites the Company's decision making and informs teammates on how to act in the absence of specific guidance.

Capital, liquidity, and resolution and recovery planning are overseen by various oversight committees. Regular reporting is provided to the Board of Directors and Executive Leadership on the assessments of risk, stress test results, and governance of the models and tools used for these processes including CAP.

The Board of Directors meets regularly to provide oversight regarding the management, objectives, and goals of the organization with regard to capital adequacy. Stress testing methodologies ensure the information provided captures forecasted losses for all material elements of the balance sheet and income statement. These results are provided for the baseline and stress scenarios, enabling the Board of Directors and risk committees to review expected performance against capital goals, targets, and risk appetite.

Refer to the "Risk Management" and "Capital" sections of the MD&A in Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended June 30, 2022 for more information regarding the Company's risk management framework and CAP.

## **Credit Risk**

Credit risk is the risk to current or anticipated earnings or capital arising from the default, inability, or unwillingness of a borrower, obligor, or counterparty to meet the terms of any financial obligation to Truist or otherwise perform as agreed. Credit risk exists in all activities where success depends on the performance of a borrower, obligor, or counterparty. Credit risk arises when Truist funds are extended, committed, invested, or otherwise exposed through actual or implied contractual agreements, whether on or off-balance sheet. Credit risk increases when the credit quality of an issuer whose securities or other instruments the bank holds deteriorates.

Truist has established the following general practices to manage credit risk:

- limiting the amount of credit that Truist may extend to a borrower;
- · establishing a process for credit approval accountability;
- · careful initial underwriting and analysis of borrower, transaction, market, and collateral risks;
- ongoing servicing and monitoring of individual loans and lending relationships;
- continuous monitoring of the portfolio, market dynamics, and the economy; and
- periodically reevaluating the Company's strategy and overall exposure as economic, market, and other relevant conditions change.

Truist regularly monitors various segments of its credit portfolios to assess potential concentration risks. Management is actively involved in the credit approval and review process, and risk acceptance criteria are adjusted as needed to reflect the Company's risk appetite. Consistent with established risk management objectives, the Company utilizes various risk mitigation techniques, including collecting collateral and security interests, obtaining guarantees, and, to a limited extent, through the purchase of credit loss protection via third party insurance and/or use of credit derivatives such as CDS.

The Company categorizes its loan portfolio into three segments: commercial lending, consumer lending, and credit card. The Company further disaggregates its commercial and consumer loans into various classes based on their underlying risk characteristics.

In the commercial portfolio, risk concentrations are evaluated regularly on both an aggregate portfolio level and on an individual client basis. The Company manages its commercial exposure through portfolio targets, limits, and transactional risk acceptance criteria as well as other techniques, including but not limited to, loan syndications/participations, loan sales, collateral, structure, covenants, and other risk-reduction techniques. The accompanying disclosures are presented net of participations sold.

In the consumer portfolio, concentrations are evaluated based on purpose, geographic location, and risk characteristics such as credit rating, loan-to-value ratio, and term, with a focus on trends and concentrations at the portfolio level where potential risk concentrations can be remedied through changes in underwriting policies and portfolio guidelines.

Additional disclosures related to the Company's credit exposures and credit risk policies are included in Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended June 30, 2022.

#### Maturities

The following tables provide the remaining maturity distribution by category for loans and leases and off balance sheet credit commitments, which includes unfunded commitments and letters of credit. The contractual amounts of off balance sheet credit commitments represent the maximum exposure to credit loss in the event of default by the borrower if the borrower were to fully draw against the commitment. The Company manages this credit risk using the same credit policies it applies to loans. Management assesses the borrower's credit worthiness to determine the necessary collateral, which may include marketable securities, receivables, inventory, equipment, and real estate. For additional information, refer to the "Lending Activities" section of the MD&A in Truist's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended June 30, 2022.

# Table 5-1 Carrying Amount of Loans and Leases by Maturity and Exposure Type June 30, 2022

One Veer a

	One	Year and							
(Dollars in millions)		Less		1 to 5 Years		5 to 15 Years		er 15 Years	Total
Commercial:									
Commercial and industrial	\$	27,840	\$	81,764	\$	32,174	\$	8,062	\$ 149,840
CRE		2,750		14,045		5,304		50	22,149
Commercial construction		59		4,500		584		14	5,157
Retail:									
Residential mortgage		24		636		4,844		45,399	50,903
Residential home equity and direct		617		7,427		8,544		8,757	25,345
Indirect auto		295		13,734		13,390		_	27,419
Indirect other		201		4,537		2,960		4,263	11,961
Student (1)		_		_		_		6,144	6,144
Credit card		4,744				_		_	4,744
Total	\$	36,530	\$	126,643	\$	67,800	\$	72,689	\$ 303,662

(1) Student loans are presented with maturities of fifteen years or more. The majority of student loan agreements held by the Company do not define maturity dates because the start of loan repayment depends on the types of deferment periods and grace periods offered.

The ending and average contract (notional) amounts of off balance sheet credit commitments, excluding those commitments considered derivatives, are shown below. Average amounts are based upon the simple average of the current and prior quarter ending balances.

## Table 5-2 Off Balance Sheet Credit Commitments Maturity by Exposure Type June 30, 2022

	0011		,								
One	e Year and Less	o 5 Years	5 t	o 15 Years	After 15 Years			Total (1)		Average Balance	
\$	35,708	\$	94,193	\$	4,508	\$	408	\$	134,817	\$	132,971
	493		1,034		154		_		1,681		1,482
	1,006		5,900		193		54		7,153		6,926
	2		_		100		7,648		7,750		6,200
	3,265		11,301		16,290		411		31,267		31,207
	_		_		_		_		_		1
	23,901		_		_		_		23,901		23,931
\$	64,375	\$	112,428	\$	21,245	\$	8,521	\$	206,569	\$	202,718
\$	2,337	\$	2,309	\$	234	\$	—	\$	4,880	\$	4,980
	34		8						42		39
	\$	One Year and Less           \$ 35,708           493           1,006           2           3,265           2           23,901           \$ 64,375           \$ 2,337	One Year and Less         1 t           \$ 35,708         \$ 493           1,006         1           2         3,265            23,901           \$ 64,375         \$           \$ 2,337         \$	One Year and Less         1 to 5 Years           \$ 35,708         \$ 94,193           493         1,034           1,006         5,900           2         —           3,265         11,301           —         —           23,901         —           \$ 64,375         \$ 112,428           \$         2,337         \$ 2,309	One Year and Less         1 to 5 Years         5 tr         \$           \$         35,708         \$         94,193         \$           493         1,034         1         1         1           1,006         5,900         1         1           2          3,265         11,301             2            23,901             \$         64,375         \$         112,428         \$           \$         2,337         \$         2,309         \$	One Year and Less         1 to 5 Years         5 to 15 Years           \$ 35,708         \$ 94,193         \$ 4,508           493         1,034         154           1,006         5,900         193           2         —         100           3,265         11,301         16,290           —         —         —           23,901         —         —           \$ 64,375         \$ 112,428         \$ 21,245           \$         2,337         \$ 2,309         \$ 234	One Year and Less         1 to 5 Years         5 to 15 Years         After A	Less         1 to 5 Years         5 to 15 Years         After 15 Years           \$ 35,708         \$ 94,193         \$ 4,508         \$ 408           493         1,034         154            1,006         5,900         193         54           2          100         7,648           3,265         11,301         16,290         411                 23,901              \$ 64,375         \$ 112,428         \$ 21,245         \$ 8,521           \$ 2,337         \$ 2,309         234         \$	One Year and Less         1 to 5 Years         5 to 15 Years         After 15 Years           \$ 35,708         \$ 94,193         \$ 4,508         \$ 408         \$ 403         \$ 1,034         \$ 154         \$ 1,006         5,900         193         54         \$ 54         \$ 54         \$ 54         \$ 54           2          100         7,648         \$ 411         \$ 54         \$ 54         \$ 54         \$ 54           2          100         7,648         \$ 54         \$ 54         \$ 54         \$ 54         \$ 54         \$ 54           2          100         7,648         \$ 54         \$ 56	One Year and Less         1 to 5 Years         5 to 15 Years         After 15 Years         Total (1)           \$ 35,708         \$ 94,193         \$ 4,508         \$ 408         \$ 134,817           493         1,034         154          1,681           1,006         5,900         193         54         7,153           2          100         7,648         7,750           3,265         11,301         16,290         411         31,267                  23,901           23,901            23,901           23,901            \$ 64,375         \$ 112,428         \$ 21,245         \$ 8,521         \$ 206,569           \$         2,337         \$ 2,309         \$ 234         \$         \$ 4,880	One Year and Less         1 to 5 Years         5 to 15 Years         After 15 Years         Total (1)           \$ 35,708         \$ 94,193         \$ 4,508         \$ 408         \$ 134,817         \$ 493           493         1,034         154          1,681           1,006         5,900         193         54         7,153           2          100         7,648         7,750           3,265         11,301         16,290         411         31,267                  23,901           23,901            23,901           23,901            \$ 64,375         \$ 112,428         \$ 21,245         \$ 8,521         \$ 206,569         \$           \$         2,337         \$ 2,309         \$ 234          \$ 4,880         \$

(1) Approximately \$51.9 billion are unconditionally cancellable for the purposes of calculating regulatory capital.

(2) The maturities of residential mortgage loan commitments are based on the loan maturities upon funding.

(3) Excludes \$3.8 billion of unfunded commitments and \$803 million of letters of credit that have been conveyed to others.

## **Geographic Disclosures**

The following tables provide the geographical distribution of commercial and consumer exposures. For the geographic disclosures, amounts are generally assigned to a state based on the physical billing address of the client or physical property address. The credit exposure includes loans and contractual commitments to extend credit. Commercial loans that are 90 days or more past due and accruing interest are immaterial. Government guaranteed loans are not placed on nonaccrual status regardless of delinquency because collection of principal and interest is reasonably assured. The past due status of loans that received a deferral under the CARES Act is generally frozen during the deferral period. In certain limited circumstances, accommodation programs result in the delinquency status being reset to current.

Table 5-3
Commercial Credit Exposure by Geography
June 30, 2022

	Julie Ju	Julie 30, 2022								
			Accruing				erforming			
(Dollars in millions)		LHFI	30-8	89 Days Past Due		nt Without	Amo	ount With an ALLL		Jnfunded mmitments
Commercial and industrial:									Johnnahona	
Florida	\$	19,372	\$	36	\$	26	\$	56	\$	11,560
Texas		14,942	•	14	,	_	•	40		14,211
Georgia		13,579		17		11		9		9,477
North Carolina		13,263		11		29		9		8,577
Virginia		9,851		10		_		76		11,037
New York		7,687		21		16		32		8,143
Pennsylvania		7,267		4		14		15		5,678
Maryland		6,460		8		_		5		5,329
California		6,454		62		_		1		11,243
Tennessee		5,771		4		_		2		4,445
South Carolina		4,170		3		_		1		2,148
Ohio		3,843		_		_		_		3,436
Illinois		3,710		_		_		_		3,690
New Jersey		3,110		1		_		1		3,122
Other		30,361		32		32		18		32,721
Total commercial and industrial	\$	149,840	\$	223	\$	128	\$	265	\$	134,817
CRE:		- ,			,		,		,	- ,-
Florida	\$	3,009	\$	1	\$	7	\$	4	\$	129
North Carolina		2,916		1		_		_		270
Georgia		2,080		4		_		3		84
California		1,751		_		_		_		151
Virginia		1,658		1		_		_		159
Texas		1,491		_		_		_		120
Pennsylvania		1,246		_		_		2		109
Maryland		1,222		_		_		_		47
New York		1,129		2		_		1		335
District of Columbia		899		_		_		_		101
Other		4,748		1		1		1		176
Total CRE	\$	22,149	\$	10	\$	8	\$	11	\$	1,681
Commercial construction:		, -		-	,	-				,
North Carolina	\$	847	\$	_	\$	_	\$	_	\$	1,323
Texas		823	•	2	,	_	•	_		1,089
Georgia		605		2		_		_		1,062
Florida		563		_		_		_		952
New York		258		_		_		_		226
Other		2,061		_		_		_		2,501
Total commercial construction	\$	5,157	\$	4	\$	_	\$	_	\$	7,153
Total commercial	\$	177,146	\$	237	\$	136	\$	276	\$	143,651

## Table 5-4 Consumer Credit Exposure by Geography June 30, 2022

			Accruing				Nonperforming							
(Dellars in millions)			30-8	39 Days Past				Without				Unfunded		
(Dollars in millions) Residential mortgage:		LHFI		Due	Past Due (1)		an A	LLL	ALLL			Commitments		
Florida	\$	7,578	\$	79	\$	95	\$	_	\$	49	\$	825		
Virginia	φ	5,808	φ	52	φ	93	φ	_	φ	49 34	φ	501		
North Carolina		5,808		66		85		_		30		574		
				51		102		1		30 27		320		
Maryland		4,778		51		76				26				
Georgia		4,615						1				440		
California		3,899		12		12		_		15		672		
Texas		2,560		27		61		—		8		845		
South Carolina		1,877		24		28		_		8		162		
Washington		1,395		4		5		—		2		432		
District of Columbia		1,351		11		6		_		7		98		
Tennessee		1,233		12		20		—		3		232		
Colorado		1,198		5		8		_		2		400		
New Jersey		1,096		9		18				4		264		
Pennsylvania		1,054		29		31		_		16		149		
Massachusetts		1,047		7		11		—		—		264		
Illinois		841		10		24		_		4		286		
New York		663		7		23		_		8		102		
Other		4,620		80		208		2		22		1,184		
Total residential mortgage	\$	50,903	\$	535	\$	911	\$	4	\$	265	\$	7,750		
Residential home equity and direct:														
Florida	\$	4,941	\$	26	\$	2	\$	—	\$	43	\$	6,779		
North Carolina		3,114		10		1		_		17		5,825		
Virginia		2,855		14		2		_		20		5,185		
Georgia		2,531		13		2		_		15		3,238		
Pennsylvania		1,479		7		1		1		14		1,817		
Maryland		1,377		10		1		1		12		2,143		
Texas		1,365		7		_		_		5		652		
South Carolina		1,012		3		_		_		5		1,798		
Tennessee		1,003		5		1				6		1,589		
California		858		3		_		_		2		197		
Other		4,810		58						18		2,044		
Total residential home equity and direct	\$	25,345	\$	156	\$	10	\$	2	\$	157	\$	31,267		
Indirect auto:	<u> </u>	20,010	•		•		¥		<u> </u>		<u> </u>	0.,20.		
Texas	\$	4,320	\$	98	\$	_	\$	1	\$	39	\$	_		
Florida	Ŷ	3,636	Ŷ	60	Ŷ	_	Ŷ		Ψ	24	Ψ			
North Carolina		3,155		45		_		_		18		_		
Georgia		2,553		46		_		_		22				
Virginia		1,581		22						10				
Maryland		1,353		20		_		_		9		_		
South Carolina		1,353		18				_		9				
Alabama				21		_		_		9		_		
		1,146				_								
Pennsylvania		932		24		-		_		10 7		_		
Tennessee		928		14		_		—						
New York		720		17		-		-		9		_		
New Jersey		544		11				—		4		_		
Mississippi		511		12		_		_		5		_		
Other		4,762		176		1		3		67		_		
Total indirect auto	\$	27,419	\$	584	\$	1	\$	4	\$	240	\$			

## Table 5-4 Consumer Credit Exposure by Geography June 30, 2022

		-									
		Accruing					Nonperforming				
(Dollars in millions)	LHFI	30-	89 Days Past Due		or More Days Past Due (1)		ount Without an ALLL		int With an ALLL		Infunded nmitments
Indirect other:											
Texas	\$ 1,560	\$	12	\$	1	\$	_	\$	2	\$	_
Florida	1,390		7		_		_		1		_
California	956		9		1		_		1		_
North Carolina	563		3		_		_		_		_
New York	467		3		_		_		_		_
Other	7,025		44		1		_		2		_
Total indirect other	\$ 11,961	\$	78	\$	3	\$	_	\$	6	\$	_
Student:											
Pennsylvania	\$ 551	\$	45	\$	66	\$	_	\$	_	\$	_
Texas	470		35		64		_		_		_
New York	455		34		60		_		_		_
California	430		28		44		_		_		_
Florida	394		25		48		_		_		_
Other	3,844		286		519		_		_		_
Total student	\$ 6,144	\$	453	\$	801	\$	_	\$	_	\$	_
Total consumer	\$ 121,772	\$	1,806	\$	1,726	\$	10	\$	668	\$	39,017

(1) Includes government guaranteed residential mortgages of \$884 million and government guaranteed student loans of \$796 million as of June 30, 2022.

## Table 5-5 Credit Card Exposure by Geography June 30, 2022

Accruing

		-			•	
June 30, 2022 _(Dollars in millions)	LHFI		30-89 Days Past Due	90 or More Days Past Due		funded mitments
North Carolina	\$	937	\$8	\$ 4	\$	4,478
Florida		920	11	7		5,235
Virginia		744	6	4		3,879
Georgia		568	6	3		2,686
Maryland	:	294	3	2		1,468
Other	1,	281	14	8		6,155
Total credit card	\$ 4,	744	\$ 48	\$ 28	\$	23,901

There are no nonperforming credit card loans as they are charged-off rather than being reclassified as nonperforming.

## Investment Securities

Truist invests in securities allowable under bank regulations. These securities are classified as AFS and HTM and may include obligations of the U.S. Treasury, U.S. government agencies, GSEs (including MBS), bank eligible obligations of any state or political subdivision, non-agency MBS, structured notes, bank eligible corporate obligations (including corporate debentures), commercial paper, negotiable CDs, bankers acceptances, mutual funds, and limited types of equity securities. The most important feature management relies on when assessing credit risk for U.S. Treasury securities and Agency MBS is the guarantee of the Federal government or its agencies.

U.S. Treasury, GSE, and Agency MBS represented 97% of the total securities portfolio as of June 30, 2022.

#### Industry Disclosures

The following tables provide industry distribution by major types of commercial credit exposure. The credit exposure includes loans and contractual commitments to extend credit. Commercial loans that are 90 days or more past due and accruing interest are immaterial. Industry classification for commercial and industrial loans is based on the North American Industry Classification System. Commercial real estate loans are classified based on type of property. Consumer credit exposures and credit card exposures have been excluded from these tables.

Table 5-6
<b>Commercial Credit Exposure by Industry</b>
June 30, 2022

		/	Accruing	Nonper	rforming	-	
(Dollars in millions)	LHFI	30-8	9 Days Past Due	Amount Without an ALLL	Amount With an ALLL		Unfunded ommitments
Commercial and industrial:							
Finance and insurance	\$ 18,989	\$	8	\$ —	\$ —	\$	20,388
Manufacturing	13,736		4	1	52		21,631
Health care and social assistance	12,866		9	_	42		6,101
Retail trade	11,195		9	_	1		15,079
Real estate and rental and leasing	9,614		23	_	6		8,832
Public administration	8,812		13	_	2		1,296
Wholesale trade	8,702		2	14	1		8,714
Information	6,454		1	18	3		9,314
Transportation and warehousing	6,282		4	6	3		6,386
Educational services	4,985		10	_	_		1,536
Professional, scientific, and technical services	4,551		6	_	33		6,327
Utilities	4,310		60	_	_		6,963
Mining, quarrying, and oil and gas extraction	3,488		1	_	8		4,316
Administrative and support and waste management and remediation services	3,355		17	11	70		2,808
Construction	3,099		10	_	5		4,316
Other	9,449		33	39	24		8,297
Subtotal	 129,887		210	89	250		132,304
Business owner occupied	 19,953		13	39	15		2,513
Total commercial and industrial	\$ 149,840	\$	223	\$ 128	\$ 265	\$	134,817
CRE:				· ·			
Office	\$ 5,309	\$	1	\$ 1	\$ 7	\$	293
Retail	4,811		4	_	2		96
Multifamily	4,334		_	_	1		283
Hotel	2,837		1	_	_		15
Industrial	2,517		_	_	_		452
Other	2,341		4	7	1		542
Total CRE	\$ 22,149	\$	10	\$ 8	\$ 11	\$	1,681
Commercial construction:				· ·			
Multifamily	\$ 2,025	\$	2	\$ —	\$ —	\$	3,709
Single Family - CP	1,105		2	· _	·		1,874
Industrial	560		_	_	_		764
Office	471		_	_	_		313
Single Family - AD and CL	300		_	_	_		166
Other	696		_	_	_		327
Total commercial construction	\$ 5,157	\$	4	\$ —	\$ —	\$	7,153
Total commercial	\$ 177,146	\$	237	\$ 136	\$ 276	\$	143,651

#### Counterparty Credit Risk-Related Exposures

Counterparty credit risk is the risk that a counterparty to a transaction with the Company fails to perform. This risk is a byproduct of transactions undertaken by the Company to facilitate a client's financing and hedging needs and can also result from the Company's normal balance sheet management, risk management, and funding activities. Counterparty risk is a category of credit risk often associated with capital markets activities, including OTC derivatives and securities financing.

For further information on counterparty credit risk, refer to "Risk Management" in the MD&A, "Note 3. Securities Financing Activities" and "Note 16. Derivative Financial Instruments" in the Truist's Quarterly Report on Form 10-Q for the period ended June 30, 2022 and "Note 1. Basis of Presentation" in Truist's Annual Report on Form 10-K for the year ended December 31, 2021.

#### OTC derivatives

As a dealer and market maker, the Company uses OTC derivatives primarily to support client hedging and risk management activities, as well as in an end-user capacity to manage its own balance sheet risk exposures. As a financial entity, certain interest rate swaps and CDS transactions entered into by the Company or its subsidiaries are subject to mandatory clearing. At June 30, 2022, the Company had \$105 million in notional amount of purchased non-cleared OTC credit derivatives related to management of its own balance sheet risk exposures. Additionally, the Company had \$2.9 billion of purchased notional and \$5.1 billion of sold notional OTC credit derivatives to support client hedging and risk management activities. Additional details of the Company's use of derivatives are included in "Note 16. Derivative Financial Instruments" in the Truist's June 30, 2022 Form 10-Q.

Counterparty credit risk management is integrated into the Company's credit risk management function. For transactions that generate meaningful counterparty credit risk, credit officers first perform a credit underwriting of the counterparty and assign an internal risk rating, before finally determining an aggregate credit exposure limit. Furthermore, if multiple underlying products and risk exposures are involved, then separate limits are assigned for each product with the counterparty. The counterparty exposure arising from OTC derivatives and securities lending transactions is aggregated with all other borrower exposures for risk management purposes.

In addition to counterparty selection and ongoing monitoring, documentation and collateral management are central to the Company's counterparty risk management efforts. Transactions are typically executed under master netting agreements. These documents provide a variety of legal protections, most notably the ability to close out all trades under that agreement on a net basis in the event of a counterparty default. The Company's legal department chairs a committee that reviews master netting agreements to confirm the enforceability of netting and collateral arrangements and generally obtains third party legal opinions regarding enforceability.

The regulatory requirement to centrally clear eligible derivative transactions with eligible CCPs has reduced the Company's counterparty credit exposure to dealers; however it has in turn increased its exposure to CCPs. The Company manages its exposure to CCPs using the same risk management practices as used for other counterparties and in accordance with supervisory guidance.

The values of OTC derivatives are based on the movement in one or more underlying variables (e.g., interest rates, credit spreads, foreign exchange rates, etc.). For internal risk management purposes, the Company establishes credit limits based on a measure of PFE, a statistical measure (at a high confidence interval) of the amount that a counterparty could owe the Company at some future point in time, taking into account collateral requirements and legally enforceable netting arrangements. The PFE, current credit exposure or mark-to-market, and collateral values, if applicable, are refreshed daily and used to calculate total counterparty credit exposure, which is compared against pre-established limits. The Company has an established limit exception management process in place which identifies, escalates, remediates, and documents any risk exposures that may exceed limits. As a bank subject to the standardized approach, RWA for OTC derivatives is determined using the methodology prescribed in the Rule for calculating PFE, and as such, the Company does not use its internal model generated PFE for that purpose.

The Company typically establishes zero threshold margin arrangements with dealers, governed under ISDA/CSA documents, such that when the fair value of a derivative changes, the out-of-the-money counterparty posts collateral to the in-the-money counterparty; collateral is generally exchanged on a daily basis. OTC derivative transactions with non-dealer clients are generally not subject to the same margin arrangements; however, they are still subject to master netting arrangements and the Company uses other available risk management techniques when necessary.

For OTC derivative transactions subject to a CSA, the Company typically only accepts high quality, liquid collateral instruments such as cash, U.S. Treasury, or agency-issued instruments, subject to applicable haircuts, as necessary. This collateral generally qualifies as financial collateral pursuant to the Rule. Cash represents the majority of the Company's collateral positions and is typically held in the Company's account or at another financial institution. Securities collateral is held at the Company's custodian bank in the Company's name and is generally controlled by the Company. In limited circumstances, collateral may be posted to an independent custodian bank for the benefit of the Company; in these circumstances, the Company does not have direct control over the collateral.

All OTC derivative transactions subject to margining requirements are monitored daily by an independent control function to ensure that collateral calls are issued and met in a timely manner. This function also ensures that any excess collateral posted by the Company to a counterparty is actively managed and withdrawn when no longer required. All collateral is valued daily. The collateral control function follows established procedures to resolve any disputes on the amount of collateral required, and escalation procedures are in place to ensure senior management is informed of any material disputes on a timely basis. In a limited number of situations, the Company's CSAs contain ratings based thresholds, such that the Company would need to post additional collateral to the degree that it suffered a credit downgrade.

Derivative instruments are priced using observable market inputs at a mid-market valuation point and take into consideration appropriate valuation adjustments for collateral, market liquidity, and counterparty credit risk. For purposes of determining fair value adjustments to its derivative positions, the Company takes into consideration the credit profile and likelihood of default by counterparties and itself, as well as, its net exposure, which considers legally enforceable master netting agreements and financial collateral along with remaining maturities. The expected loss of each counterparty, the CVA, is estimated using market-based views of counterparty default probabilities observed in the single-name CDS market, when available and of sufficient liquidity. When single-name CDS market data is not available or not of sufficient liquidity, the probability of default is estimated using a combination of the Company's internal risk rating system and sector/rating based CDS data.

For purposes of estimating the Company's own credit risk on derivative liability positions, the DVA, the Company uses probabilities of default from observable, sector/rating based CDS data. Information on the Company's fair value measurements can be found in the Company's June 30, 2022 Form 10-Q in "Note 15. Fair Value Disclosures."

## Securities financing

The securities financing market encompasses both repurchase and reverse repurchase agreements, as well as securities lending/ borrowing transactions. These transactions are structured such that borrowers post collateral in exchange for the ability to borrow cash or securities. Securities financing transactions enable cost-effective borrowing for clients and the Company and facilitate a variety of market making activities. Truist's securities financing transactions are subject to the same risk management procedures, and applicable RWA calculations consider eligible collateral and/or the counterparty to the underlying transaction.

Securities financing transactions are typically secured by high-quality, liquid collateral. The Company establishes limits on counterparties using the Basel Collateral Haircut methodology, measuring in this case the amount that the Company could lose if it were forced to close out the transaction ahead of scheduled maturity in a stressed situation. The Company may supplement its credit limits with notional limits based on the counterparty and/or the size of the financing arrangement.

Securities financing transactions provide for the regular movement of collateral so that the lender maintains an appropriate margin. The Company monitors its securities financing positions on a daily basis and calls for additional collateral as needed. The collateral received is typically held in an account with the Company's securities custodian.

## **Credit Risk Mitigation**

The Rule allows eligible financial collateral, guarantees, and credit derivatives to be recognized in the calculation of RWA. The Company's use of credit risk mitigants in the calculation of RWA includes eligible collateral primarily in the form of U.S. Treasury or agency securities as well as cash. When financial collateral is obtained that qualifies as eligible collateral under the Rule, the eligible collateral can be substituted for the collateralized portion of the credit exposure in the RWA calculation. Similarly, when an eligible guarantee is received, the risk weight applicable to the eligible guarantor would apply to the exposure amount covered by the guarantee.

The following table summarizes OTC derivative contracts covered by eligible collateral:

# Table 7-1 Total Exposure of OTC Derivative Contracts Covered by Eligible Collateral June 30, 2022

_(dollars in millions)	Gross Current Credit Exposure	Potential Future Exposure	Total Exposure
Interest rate	\$ 766	\$ 359	\$ 1,125
Credit	89	2	91
Commodity	1,067	487	1,554
Risk participation agreements	20	41	61
Foreign exchange	450	214	664
Equities	336	517	853
Total derivative gross credit exposure	2,728	1,620	4,348
Amounts subject to master netting arrangements	(1,077)	) —	(1,077)
Collateral held	(363)	· —	(363)
Net exposure for derivatives covered by eligible collateral	\$ 1,288	\$ 1,620	\$ 2,908

Truist has certain loans and other assets totaling approximately \$8.7 billion with guarantees by the U.S. government. This includes \$681 million of PPP loans, which receive a zero percent risk weight.

#### **Securitizations**

#### Overview

The Basel III framework for securitizations addresses the capital treatment for exposures that involve the tranching of credit risk and categorizes securitizations as either traditional or synthetic.

The Rule describes securitization transactions as:

- All or a portion of the credit risk of one or more underlying exposures is transferred to one or more third parties other than through the use of credit derivatives or guarantees;
- The credit risk associated with the underlying exposures has been separated into at least two tranches reflecting different levels of seniority;
- · Performance of the securitization exposures is solely dependent on the performance of the underlying exposures; and
- All or substantially all of the underlying exposures are financial exposures.

A synthetic securitization shares the same attributes as a traditional securitization, except that all or a portion of the credit risk of one or more underlying assets is retained or transferred to one or more third parties through the use of one or more credit derivatives or guarantees.

Any securitization where one or more of the underlying exposures are a securitization exposure is considered to be a resecuritization. The Company did not have resecuritization exposures at June 30, 2022.

#### Securitization process

The Company's current exposure to securitizations primarily includes loans to SPEs (not sponsored by the Company) that are designed to meet client needs for long-term financing of assets or working capital. These securitization arrangements assist the Company's clients in funding their financial assets. The Company also has securitization exposures in the form of non-agency mortgage-backed securities within its available for sale portfolio. Exposure amounts at June 30, 2022 are provided below in Tables 8-1 and 8-2.

The Company also originates and sells certain mortgages to Fannie Mae and Freddie Mac and issues and sells Ginnie Mae MBS. The Company transfers loans to securitization entities sponsored by these agencies. The loans are exchanged for cash or securities that are readily redeemable for cash, with servicing rights retained. The Company has made certain representations and warranties with respect to the transfer of these loans and has entered into a loss share guarantee related to certain loans transferred to Fannie Mae.

At June 30, 2022, the Company held \$181 million of LHFS that it intends to securitize with Ginnie Mae. The Company periodically evaluates securitizations as a source of alternate financing; however, it does not expect securitization to comprise a significant amount of total funding.

## Due diligence

The Company analyzes the credit profile of each securitization exposure prior to entering into that position, and documents such due diligence within the timeframe required under the Rule. The due diligence procedures are designed to provide the Company with a comprehensive understanding of the features that would materially affect the performance of its exposures.

The Company's due diligence procedures include analyzing and monitoring:

- · Information regarding the performance of the underlying credit exposures and relevant market data;
- · Structural and other enhancement features that may affect the credit quality of a securitization; and
- Credit profile of the seller/servicer of the assets securitized.

The level of detail included in the due diligence procedures is commensurate with the complexity of each securitization position held. In addition to pre-trade due diligence, the due diligence procedures are also performed on a periodic basis for each securitization position.

#### Risks

Securitization transactions involve a number of risks including credit risk and seller/servicer risk. Credit risk arises where the underlying assets fail to perform (e.g., payment rates, dilution, write-offs/losses), such that the credit enhancement is insufficient to protect the Company's investment. Seller/servicer risk represents the reliance on the seller and/or servicer of the assets to perform its duties under the securitization agreement and make certain representations and warranties as to the underlying collateral. The risks in the securitization loan portfolio are monitored monthly by comparing performance of assets to the structural requirements. The Company manages these risks (both pre and post commencement of a position) as part of its comprehensive risk management framework, which is described in the Company's June 30, 2022 Form 10-Q.

#### Risk-based capital approach

The Basel III standardized approach requires the application of the SSFA or, if not subject to the Market Risk Rule, the gross-up approach for calculating RWA for securitization exposures. The Company is subject to the Market Risk Rule and, therefore, applies the SSFA to its securitization exposures. A risk weight of 1,250% must be applied to a securitization exposure where the Company does not apply the SSFA.

The SSFA requires the following inputs to calculate regulatory capital:

- Attachment Point: the point at which collateral losses from underlying assets backing a securitization tranche will first be applied to the tranche in the form of principal write-downs;
- Detachment Point: the point at which the tranche will be completely written-down as a result of losses from the collateral backing the tranche;
- Weighted Average Capital: the weighted average capital charge for the assets in the securitization;
- Seriously Delinquent: the percentage of underlying collateral that is seriously delinquent (e.g., 90+ days past due, in foreclosure, in bankruptcy); and
- Calibration Parameter: a parameter that increases the riskiness of a tranche for re-securitizations.

The risk-based capital requirement under the SSFA is the exposure amount (including any accrued interest receivable on the exposure) multiplied by the higher of either the calculated risk weight, determined by the inputs listed above, or a 20% risk weight.

#### Risk-weighted assets for securitization exposures

The following table presents securitization exposures and their applicable risk weighting as of June 30, 2022. There were no amounts of exposures past due and impaired as of June 30, 2022, and no losses were incurred on the exposures during the quarter ended June 30, 2022.

#### Table 8-1 Total Securitizations by Risk Weight Category June 30, 2022

(dollars in millions)	osure ount	RWA	RWA %	RWA Method
Exposure type:				
LHFI	\$ 5,455	5 1,411	26 %	SSFA
Unfunded commitment related to LHFI	3,689	1,036	28	SSFA
Securities AFS:				
Securitization (1)	4,068	814	20	SSFA
Other off-balance sheet amount (2)	18	225	1250 %	1250 %
Other	8	2	25 %	SSFA
Total securitization	\$ 13,238	3,488		

(1) Includes accrued interest.

(2) For off-balance sheet exposures that use the 1,250% risk-weight, the exposure amount equals the maximum exposure to loss.

The following table presents securitization exposures and underlying collateral type as of June 30, 2022.

## Table 8-2 Securitizations by Collateral Type June 30, 2022

	 Se	ecurit	ization Amou	unt		
(dollars in millions)	On Balance Sheet	0	ff Balance Sheet		Total	RWA
Collateral type:						
Trade receivables	\$ 943	\$	793	\$	1,736	\$ 350
Commercial and Industrial	951		408		1,359	272
Consumer Loans	1,765		1,203		2,968	940
Residential Mortgages	4,050		_		4,050	810
Other	1,822		1,303		3,125	1,116
Total	\$ 9,531	\$	3,707	\$	13,238	\$ 3,488

## Equity Securities Not Subject to Market Risk Rule

The Company holds equity securities for various purposes. The Company's investments in private equity funds are generally held to realize a potential profit; equity securities in pension plans are held to reduce future pension expense; investments in affordable housing are made to generate tax credits and investments in certain trade organizations are required to realize the benefits of being a member.

The Company has total equity exposures of approximately \$15.9 billion, with \$4.6 billion in individual equities and \$11.3 billion in equity funds at June 30, 2022. The majority of the individual investments are related to the Company's CRA activities, including tax-advantaged investments. The Company uses the simple risk-weight approach for its individual equity securities. The equity funds consist of BOLI, private equity, pension fund assets, money market, and other equity funds. The Company uses the full look-through approach for BOLI assets in separate accounts. Investment guidelines specify objectives and constraints for separate account BOLI investment funds, including permitted and non-permitted investments, concentration and diversification requirements, credit quality requirements, and duration parameters. There were no unrealized gains not recognized through earnings included in Tier 2 capital for the quarter ended June 30, 2022.

Non-marketable equity securities are generally recorded either at historical cost or using the equity method. Refer to "Note 1. Basis of Presentation" in Truist's Annual Report on Form 10-K for the year ended December 31, 2021 for accounting policies related to equity investments and the valuation of financial instruments.

At June 30, 2022, the Company held approximately \$796 million of exposures in equity funds that relate to the Company's nonqualified defined contribution plan. There is an offsetting liability for these investments, and as a result, there is no impact to earnings or equity from these investments as changes in the fair value of the investments are recorded in income with an offsetting change in personnel expense.

Equity securities carried at cost and the related unrealized gains and losses were immaterial at June 30, 2022.

The following table summarizes the Company's equity securities not subject to the Market Risk Rule:

Table 9-1 Equity Securities Not Subject to Market Risk Rule June 30, 2022

(dollars in millions)	Exposure	RWA	•	ital Impact RWA (1)
20% risk weight	\$ 242	\$ 48	\$	4
100% risk weight	4,188	4,188		335
Full look-through approach	11,519	10,291		823
Total	\$ 15,949	\$ 14,527	\$	1,162
Public	\$ 7,055			
Nonpublic	8,894			
Total	\$ 15,949			

(1) Calculated by multiplying RWA by the minimum total risk-based capital ratio of 8%.

## **Cross Reference Table**

Note: References in the following table to Form 10-Q or Form FR Y-9C are to the respective form for the period ended June 30, 2022. References to Form 10-K are for the year ended December 31, 2021.

	Disclosure Requirement	Disclosure Location
	- Scope of Application	
	tative:	
. ,	The name of the top corporate entity in the group to which subpart D of this part applies.	Pillar 3 Regulatory Capital Disclosures: Introduction
(b)	A brief description of the differences in the basis for consolidating entities for accounting and regulatory purposes, with a description of those entities:	Pillar 3 Regulatory Capital Disclosures: Basis of Consolidation
	<ol> <li>(1) That are fully consolidated;</li> <li>(2) That are deconsolidated and deducted from total capital;</li> <li>(3) For which the total capital requirement is deducted; and</li> <li>(4) That are neither consolidated nor deducted (for example, where the investment in the entity is assigned a risk weight in accordance with this subpart).</li> </ol>	The Company does not have a difference in the basis of consolidation for accounting and regulatory purposes.
(c)	Any restrictions, or other major impediments, on transfer of funds or total capital	Form 10-K:
. ,	within the group.	Note 17. Regulatory Requirements and Other Restriction
		Note 22. Parent Company Financial Information
		Item 7 - MD&A - Liquidity Item 7 - MD&A - Capital
		<i>Form 10-Q:</i> Item 2 - MD&A - Capital
		<b>Pillar 3 Regulatory Capital Disclosures:</b> Capital Planning and Stress Testing Requirements
Quan	titative:	-
(d)	The aggregate amount of surplus capital of insurance subsidiaries included in the total capital of the consolidated group.	<b>Pillar 3 Regulatory Capital Disclosures:</b> Capital in Subsidiaries
(e)	The aggregate amount by which actual total capital is less than the minimum total capital requirement in all subsidiaries, with total capital requirements and the name(s) of the subsidiaries with such deficiencies.	Not applicable. Actual total capital is greater than the minimum total capital requirement.
able 2	- Capital Structure	
Quali	tative:	
(a)	Summary information on the terms and conditions of the main features of all	Form 10-K:
	regulatory capital instruments.	Note 11. Borrowings
		Note 12. Shareholders' Equity
		Form 10-Q:
		Note 9. Borrowings
		Note 10. Shareholders' Equity
		Item 2 - MD&A - Capital
		Item 2 - MD&A - Funding Activities
		Pillar 3 Regulatory Capital Disclosures:
		Capital Structure
	titative:	5
(b)	The amount of common equity tier 1 capital, with separate disclosure of:	Form FR Y-9C:
	(1) Common stock and related surplus;	Schedule HC-R
	(2) Retained earnings;	
	(3) Common equity minority interest;	Form 10-Q:
	(4) AOCI; and	Consolidated Balance Sheet
	(5) Regulatory adjustments and deductions made to common equity tier 1 capital.	
(c)		Form FR Y-9C: Schedule HC-R

Disclosure Requirement	Disclosure Location
(d) The amount of total capital, with separate disclosure of:	Form FR Y-9C:
<ol> <li>Tier 2 capital elements, including tier 2 capital instruments and total capital minority interest not included in tier 1 capital; and</li> </ol>	Schedule HC-R
(2) Regulatory adjustments and deductions made to total capital.	
Table 3 - Capital Adequacy	•
Qualitative:	
(a) A summary discussion of the FDIC-supervised institution's approach to assessing the adequacy of its capital to support current and future activities.	Form 10-K: Item 7 - MD&A - Capital
	Form 10-Q: Item 2 - MD&A - Capital
Quantitative:	
<ul> <li>(b) Risk-weighted assets for: <ul> <li>(1) Exposures to sovereign entities;</li> <li>(2) Exposures to certain supranational entities and MDBs;</li> <li>(3) Exposures to depository institutions, foreign banks, and credit unions;</li> <li>(4) Exposures to PSEs;</li> <li>(5) Corporate exposures;</li> <li>(6) Residential mortgage exposures;</li> <li>(7) Statutory multifamily mortgages and pre-sold construction loans;</li> <li>(8) HVCRE loans;</li> <li>(9) Past due loans;</li> <li>(10) Other assets;</li> <li>(11) Cleared transactions;</li> <li>(12) Default fund contributions;</li> <li>(13) Unsettled transactions;</li> <li>(14) Securitization exposures; and</li> </ul> </li> </ul>	Pillar 3 Regulatory Capital Disclosures: Table 3-1
<ul><li>(15) Equity exposures.</li><li>(c) Standardized market risk-weighted assets as calculated under subpart F of this part.</li></ul>	
<ul> <li>(d) Common equity tier 1, tier 1 and total risk-based capital ratios:</li> <li>(1) For the top consolidated group; and</li> <li>(2) For each depository institution subsidiary.</li> </ul>	Table 3-1         Pillar 3 Regulatory Capital Disclosures:         Table 3-3         Piller 2 Regulatory Capital Disclosures:
(e) Total standardized risk-weighted assets.	Pillar 3 Regulatory Capital Disclosures: Table 3-1
Table 4 - Capital Conservation Buffer	
Qualitative:	
<ul> <li>(a) At least quarterly, the FDIC-supervised institution must calculate and publicly disclose the capital conservation buffer as described under § 324.11.</li> </ul>	Form FR Y-9C: Schedule HC-R
(b) At least quarterly, the FDIC-supervised institution must calculate and publicly disclose the eligible retained income of the FDIC-supervised institution, as described under § 324.11.	Form FR Y-9C: Schedule HC-R
(c) At least quarterly, the FDIC-supervised institution must calculate and publicly disclose any limitations it has on distributions and discretionary bonus payments resulting from the capital conservation buffer framework described under § 324.11, including the maximum payout amount for the quarter.	Form FR Y-9C: Schedule HC-R
General Qualitative Disclosure	
For each separate risk area described in Tables 5 through 10, the FDIC-supervised institution must describe its risk management objectives and policies, including: strategies and processes; the structure and organization of the relevant risk management function; the scope and nature of risk reporting and/or measurement systems; policies for hedging and/or mitigating risk and strategies and processes for monitoring the continuing effectiveness of hedges/mitigants.	See the references to the qualitative disclosures below for each respective Pillar 3 table for the location of these disclosures for each risk area. See additional information on Corporate Governance at <u>ir.truist.com/corporate-</u> <u>governance</u> .

Disclosure Requirement	Disclosure Location
able 5 - Credit Risk: General Disclosures	
Qualitative:	
<ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk (excluding counterparty credit risk disclosed in accordance with Table 6 to § 324.63), including: <ul> <li>(1) Policy for determining past due or delinquency status;</li> <li>(2) Policy for placing loans on nonaccrual;</li> <li>(3) Policy for returning loans to accrual status;</li> <li>(4) Definition of and policy for identifying impaired loans (for financial accounting purposes);</li> <li>(5) Description of the methodology that the entity uses to estimate its allowance for loan and lease losses, including statistical methods used where applicable;</li> <li>(6) Policy for charging-off uncollectible amounts; and</li> <li>(7) Discussion of the FDIC-supervised institution's credit risk management policy.</li> </ul> </li> </ul>	Form 10-K: Note 1. Basis of Presentation Originated loans and leases NPAs ACL Item 7 - MD&A Lending activities Risk Management <i>Pillar 3 Regulatory Capital Disclosures:</i> Credit Risk
(b) Total credit risk exposures and average credit risk exposures, after accounting	Form 10-Q:
(b) rotat noise the second and an end of the second and the second	Consolidated Balance Sheet Note 4. Investment Securities Note 5. Loans and ACL Note 14. Commitments and Contingencies Note 15. Fair Value Disclosures
<ul> <li>(1) Loans, off-balance sheet commitments, and other non-derivative off-balance sheet exposures;</li> <li>(2) Delta and it is a statement of the sheet exposure of the sheet exposure</li></ul>	Note 16. Derivative Financial Instruments Item 2 - MD&A - Table 1
(2) Debt securities; and	Item 2 - MD&A - Table 6
<ul><li>(3) OTC derivatives.</li><li>(c) Geographic distribution of exposures, categorized in significant areas by major types</li></ul>	Pillar 3 Regulatory Capital Disclosures:         Table 5-1         Table 5-2         Pillar 3 Regulatory Capital Disclosures:
of credit exposure.	Geographic Disclosures Table 5-3 Table 5-4 Table 5-5 US Treasury, Agency, and Municipal Securities Counterparty Credit Risk Related Disclosures
(d) Industry or counterparty type distribution of exposures, categorized by major types of credit exposure.	Pillar 3 Regulatory Capital Disclosures: Industry Disclosures Table 5-6 Counterparty Credit Risk Related Disclosures
(e) By major industry or counterparty type:	Form 10-Q:
<ol> <li>Amount of impaired loans for which there was a related allowance under GAAP;</li> <li>Amount of impaired loans for which there was a related allowance under</li> </ol>	Note 5. Loans and ACL
<ul> <li>(2) Amount of impaired loans for which there was no related allowance under GAAP;</li> <li>(2) Amount of the second se</li></ul>	Pillar 3 Regulatory Capital Disclosures: Industry Disclosures Table 5-6
<ul><li>(3) Amount of loans past due 90 days and on nonaccrual;</li><li>(4) Amount of loans past due 90 days and on nonaccrual;</li></ul>	
(4) Amount of loans past due 90 days and still accruing;	
(5) The balance in the allowance for loan and lease losses at the end of each period, disaggregated on the basis of the entity's impairment method. To disaggregate the information required on the basis of impairment methodology, an entity shall separately disclose the amounts based on the requirements in GAAP; and	
(6) Charge-offs during the period.	
(f) Amount of impaired loans and, if available, the amount of past due loans categorized by significant geographic areas including, if practical, the amounts of allowances related to each geographical area, further categorized as required by GAAP.	<i>Pillar 3 Regulatory Capital Disclosures:</i> Geographic Disclosures Table 5-3 Table 5-4 Table 5-5

June	30,	2022
------	-----	------

Disclosure Requirement	Disclosure Location
(g) Reconciliation of changes in ALLL.	Form 10-Q;
	Note 5. Loans and ACL
(h) Remaining contractual maturity breakdown (for example, one year or less) of the whole portfolio, categorized by credit exposure.	Pillar 3 Regulatory Capital Disclosures: Table 5-1
	Table 5-2
able 6 - Credit Risk: General Disclosure for Counterparty Credit Risk-Related Expos	ures
Qualitative:	
(a) The general qualitative disclosure requirement with respect to OTC derivatives,	Form 10-K:
eligible margin loans, and repo-style transactions, including a discussion of:	Note 1. Basis of Presentation
	Note 19. Derivative Financial Instruments
(1) The methodology used to assign credit limits for counterparty credit exposures	s; Item 7 - MD&A - Risk Management
<ol> <li>Policies for securing collateral, valuing and managing collateral, and establishing credit reserves;</li> </ol>	Form 10-Q:
(3) The primary types of collateral taken; and	Note 3. Securities Financing Activities
(4) The impact of the amount of collateral the FDIC-supervised institution would	Note 16. Derivative Financial Instruments
have to provide given a deterioration in the FDIC-supervised institution's owr creditworthiness.	1
	Pillar 3 Regulatory Capital Disclosures: Counterparty Credit Risk-Related Exposures
Quantitative:	
(b) Gross positive fair value of contracts, collateral held (including type, for example,	Form 10-Q:
(s) Store points and reduce of the description and the distribution of the description	Note 16. Derivative Financial Instruments
(c) Notional amount of purchased and sold credit derivatives, segregated between use for the FDIC-supervised institution's own credit portfolio and in its intermediation activities, including the distribution of the credit derivative products used, categorized further by protection bought and sold within each product group.	<b>Pillar 3 Regulatory Capital Disclosures:</b> Credit Risk
able 7 - Credit Risk Mitigation	
able 7 - Credit Risk Mitigation Qualitative:	
able 7 - Credit Risk Mitigation	Form 10-Q: Note 16. Derivative Financial Instruments
able 7 - Credit Risk Mitigation         Qualitative:         (a) The general qualitative disclosure requirement with respect to credit risk mitigation,	
able 7 - Credit Risk Mitigation         Qualitative:         (a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:         (1) Policies and processes for collateral valuation and management;         (2) A description of the main types of collateral taken by the FDIC-supervised	Note 16. Derivative Financial Instruments <i>Form 10-K:</i> Note 1. Basis of Presentation
able 7 - Credit Risk Mitigation         Qualitative:         (a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:         (1) Policies and processes for collateral valuation and management;	Note 16. Derivative Financial Instruments <i>Form 10-K:</i> Note 1. Basis of Presentation Originated loans and leases TDRs
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> </ul></li></ul>	Note 16. Derivative Financial Instruments <i>Form 10-K:</i> Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments <i>Form 10-K:</i> Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> </ul></li></ul>	Note 16. Derivative Financial Instruments <i>Form 10-K:</i> Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul> </li> </ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk Risk Management - Market risk
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk Risk Management - Market risk Lending Activities
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk Risk Management - Market risk
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk Risk Management - Market risk Lending Activities Critical Accounting Policies - Derivative Assets and
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk Risk Management - Market risk Lending Activities Critical Accounting Policies - Derivative Assets and Liabilities
<ul> <li>able 7 - Credit Risk Mitigation Qualitative: <ul> <li>(a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:</li> <li>(1) Policies and processes for collateral valuation and management;</li> <li>(2) A description of the main types of collateral taken by the FDIC-supervised institution;</li> <li>(3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and</li> <li>(4) Information about (market or credit) risk concentrations with respect to credit risk</li> </ul></li></ul>	Note 16. Derivative Financial Instruments Form 10-K: Note 1. Basis of Presentation Originated loans and leases TDRs NPAs ACL Note 16. Commitments and Contingencies Note 18. Fair Value Disclosures Item 7 - MD&A Risk Management Risk Management - Credit risk Risk Management - Market risk Lending Activities Critical Accounting Policies - Derivative Assets and Liabilities Item 1A - Risk Factors - Credit Risk Item 1A - Risk Factors - Market Risk
able 7 - Credit Risk Mitigation         Qualitative:         (a) The general qualitative disclosure requirement with respect to credit risk mitigation, including:         (1) Policies and processes for collateral valuation and management;         (2) A description of the main types of collateral taken by the FDIC-supervised institution;         (3) The main types of guarantors/credit derivative counterparties and their creditworthiness; and         (4) Information about (market or credit) risk concentrations with respect to credit ris mitigation.         (b) For each separately disclosed credit risk portfolio, the total exposure that is covered	Note 16. Derivative Financial Instruments         Form 10-K:         Note 1. Basis of Presentation         Originated loans and leases         TDRs         NPAs         ACL         Note 16. Commitments and Contingencies         Note 18. Fair Value Disclosures         Item 7 - MD&A         Risk Management         Risk Management - Credit risk         Risk Management - Market risk         Lending Activities         Critical Accounting Policies - Derivative Assets and         Liabilities         Item 1A - Risk Factors - Credit Risk         Item 1A - Risk Factors - Market Risk

Disclosure Requirement	Disclosure Location
Table 8 - Securitization	
Qualitative:	
(a) The general qualitative disclosure requirement with respect to a securitization (including synthetic securitizations), including a discussion of:	Pillar 3 Regulatory Capital Disclosures: Securitizations
(1) The FDIC-supervised institution's objectives for securitizing assets, including the extent to which these activities transfer credit risk of the underlying exposures away from the FDIC-supervised institution to other entities and including the type of risks assumed and retained with resecuritization activity;	<i>Form 10-K:</i> Note 1. Basis of Presentation Item 7 - MD&A - Risk Management
(2) The nature of the risks (e.g. liquidity risk) inherent in the securitized assets;	
(3) The roles played by the FDIC-supervised institution in the securitization process and an indication of the extent of the FDIC-supervised institution's involvement in each of them;	
<ul> <li>(4) The processes in place to monitor changes in the credit and market risk of securitization exposures including how those processes differ for resecuritization exposures;</li> </ul>	
(5) The FDIC-supervised institution's policy for mitigating the credit risk retained through securitization and resecuritization exposures; and	
(6) The risk-based capital approaches that the FDIC-supervised institution follows for its securitization exposures including the type of securitization exposure to which each approach applies.	
(b) A list of:	Form 10-K:
(1) The type of securitization SPEs that the FDIC-supervised institution, as	Note 1. Basis of Presentation.
sponsor, uses to securitize third-party exposures. The FDIC-supervised institution must indicate whether it has exposure to these SPEs, either on- or of the sector of t	Note 18. Fair Value Disclosures
off-balance sheet; and	Form 10-Q:
(2) Affiliated entities:	Note 7. Loan Servicing
<ul> <li>(i) That the FDIC-supervised institution manages or advises; and</li> <li>(ii) That invest either in the securitization exposures that the FDIC-supervised</li> </ul>	
institution has securitized or in securitization SPEs that the FDIC- supervised institution sponsors.	
(c) Summary of the FDIC-supervised institution's accounting policies for securitization activities, including:	Form 10-K: Note 1. Basis of Presentation.
(1) Whether the transactions are treated as sales or financings;	Note 18. Fair Value Disclosures
(2) Recognition of gain-on-sale;	Form 10-Q:
<ul> <li>(3) Methods and key assumptions applied in valuing retained or purchased interests;</li> </ul>	Note 7. Loan Servicing
<ul> <li>(4) Changes in methods and key assumptions from the previous period for valuing retained interests and impact of the changes;</li> </ul>	
(5) Treatment of synthetic securitizations;	
(6) How exposures intended to be securitized are valued and whether they are recorded under subpart D of this part; and	
(7) Policies for recognizing liabilities on the balance sheet for arrangements that could require the FDIC-supervised institution to provide financial support for securitized assets.	
(d) An explanation of significant changes to any quantitative information since the last reporting period.	Pillar 3 Regulatory Capital Disclosures: Securitizations
Quantitative:	
(e) The total outstanding exposures securitized by the FDIC-supervised institution in securitizations that meet the operational criteria provided in § 324.41 (categorized into traditional and synthetic securitizations), by exposure type, separately for securitizations of third-party exposures for which the FDIC-supervised institution acts only as sponsor.	<i>Pillar 3 Regulatory Capital Disclosures:</i> Securitizations
(f) For exposures securitized by the FDIC-supervised institution in securitizations that meet the operational criteria in § 324.41:	Pillar 3 Regulatory Capital Disclosures: Securitizations
<ol> <li>Amount of securitized assets that are impaired/past due categorized by exposure type; and</li> </ol>	
(2) Losses recognized by the FDIC-supervised institution during the current period categorized by exposure type.	

	Disclosure Requirement	Disclosure Location
	he total amount of outstanding exposures intended to be securitized categorized by exposure type.	Pillar 3 Regulatory Capital Disclosures: Securitizations
(h) A	ggregate amount of:	Pillar 3 Regulatory Capital Disclosures:
	(1) On-balance sheet securitization exposures retained or purchased categorized by exposure type; and	Table 8-1
	(2) Off-balance sheet securitization exposures categorized by exposure type.	
(i) (1	<ol> <li>Aggregate amount of securitization exposures retained or purchased and the associated capital requirements for these exposures, categorized between securitization and resecuritization exposures, further categorized into a meaningful number of risk weight bands and by risk-based capital approach (e.g., SSFA); and</li> </ol>	<b>Pillar 3 Regulatory Capital Disclosures:</b> Table 8-2
	(2) Exposures that have been deducted entirely from tier 1 capital, CEIOs deducted from total capital (as described in § 324.42(a)(1)), and other exposures deducted from total capital should be disclosed separately by exposure type.	Truist does not have any securitization exposures that have been deducted from capital.
•	ummary of current year's securitization activity, including the amount of exposures securitized (by exposure type), and recognized gain or loss on sale by exposure	Form 10-K: Note 1. Basis of Presentation
	type.	Note 18. Fair Value Disclosures
		Item 7 - MD&A - Risk Management
		Form 10-Q:
		Note 7. Loan Servicing
	ggregate amount of resecuritization exposures retained or purchased categorized according to:	Form 10-K: Note 1. Basis of Presentation.
	(1) Exposures to which credit risk mitigation is applied and those not applied; and	Note 18. Fair Value Disclosures
	(2) Exposures to guarantors categorized according to guarantor creditworthiness	Item 7 - MD&A - Risk Management
		-
	categories or guarantor name.	Form 10-Q:
	categories or guarantor name.	-
able 9	categories or guarantor name.     Equities Not Subject to Subpart F of This Part	Form 10-Q:
able 9 Qualita	- Equities Not Subject to Subpart F of This Part ative:	Form 10-Q: Note 7. Loan Servicing
able 9 Qualita (a) T	- Equities Not Subject to Subpart F of This Part     ative:     he general qualitative disclosure requirement with respect to equity risk for equities     not subject to subpart F of this part, including:	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule
able 9 Qualita (a) T	- Equities Not Subject to Subpart F of This Part     ative:     he general qualitative disclosure requirement with respect to equity risk for equities	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule
<mark>able 9</mark> Qualita (a) ⊺	- Equities Not Subject to Subpart F of This Part     - Equities Not Subject to Subpart F of This Part     - Equities Not Subject to Subpart F of This Part     - Equities Not Subject to Subpart F of this part, including:     (1) Differentiation between holdings on which capital gains are expected and those     taken under other objectives including for relationship and strategic reasons;     and     (2) Discussion of important policies covering the valuation of and accounting for	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule
<mark>able 9</mark> Qualita (a) ⊺	<ul> <li>Equities Not Subject to Subpart F of This Part         ative:         he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:         (1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and         (2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the     </li> </ul>	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule
<mark>able 9</mark> Qualita (a) ⊺	<ul> <li>Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes</li> </ul>	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule Form 10-K:
<mark>able 9</mark> Qualita (a) ⊺	<ul> <li>Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> </ul>	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule Form 10-K: Note 1. Basis of Presentation
<mark>able 9</mark> Qualita (a) T ∏ Quanti	<ul> <li>Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> </ul>	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule Form 10-K: Note 1. Basis of Presentation Note 18. Fair Value Disclosures Item 7 - MD&A - Risk Management
able 9 Qualita (a) T (a) T	<ul> <li>Equities Not Subject to Subpart F of This Part         ative:         he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:         (1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and         (2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.     </li> <li>Itative:</li> <li>Yalue disclosed on the balance sheet of investments, as well as the fair value of those investments; for securities that are publicly traded, a comparison to publicly-</li> </ul>	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule Form 10-K: Note 1. Basis of Presentation Note 18. Fair Value Disclosures
able 9 Qualita (a) T (a) T	<ul> <li>Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> <li>itative:</li> </ul>	Form 10-Q: Note 7. Loan Servicing Pillar 3 Regulatory Capital Disclosures: Equity Securities Not Subject to Market Risk Rule Form 10-K: Note 1. Basis of Presentation Note 18. Fair Value Disclosures Item 7 - MD&A - Risk Management Pillar 3 Regulatory Capital Disclosures: Table 9-1 The values on the balance sheet are not materially different than the fair values of the investments. Publicly
able 9 Qualita (a) T (a) T	<ul> <li>Equities Not Subject to Subpart F of This Part         ative:         he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:         (1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and         (2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.     </li> <li>Itative:</li> <li>Yalue disclosed on the balance sheet of investments, as well as the fair value of those investments; for securities that are publicly traded, a comparison to publicly-</li> </ul>	Form 10-Q:         Note 7. Loan Servicing         Pillar 3 Regulatory Capital Disclosures:         Equity Securities Not Subject to Market Risk Rule         Form 10-K:         Note 1. Basis of Presentation         Note 18. Fair Value Disclosures         Item 7 - MD&A - Risk Management         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different than the fair values of the investments. Publicly guoted share values are not materially different from the
able 9 Qualita (a) T Quanti (b) V	<ul> <li>Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> <li>Itative:</li> <li>Yalue disclosed on the balance sheet of investments, as well as the fair value of those investments; for securities that are publicly traded, a comparison to publicly- quoted share values where the share price is materially different from fair value.</li> </ul>	Form 10-Q:         Note 7. Loan Servicing         Pillar 3 Regulatory Capital Disclosures:         Equity Securities Not Subject to Market Risk Rule         Form 10-K:         Note 1. Basis of Presentation         Note 18. Fair Value Disclosures         Item 7 - MD&A - Risk Management         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different than the fair values of the investments. Publicly quoted share values are not materially different from the fair values.
able 9 Qualita (a) T Quanti (b) V	<ul> <li>Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> <li>itative:</li> <li>'alue disclosed on the balance sheet of investments, as well as the fair value of those investments; for securities that are publicly traded, a comparison to publicly- quoted share values where the share price is materially different from fair value.</li> </ul>	Form 10-Q:         Note 7. Loan Servicing         Pillar 3 Regulatory Capital Disclosures:         Equity Securities Not Subject to Market Risk Rule         Form 10-K:         Note 1. Basis of Presentation         Note 18. Fair Value Disclosures         Item 7 - MD&A - Risk Management         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different than the fair values of the investments. Publicly quoted share values are not materially different from the fair values.         Pillar 3 Regulatory Capital Disclosures:
able 9 Qualita (a) T (a) T (b) V (c) T (c) T	<ul> <li>Equities Not Subject to Subpart F of This Part ative:</li> <li>he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> <li>itative:</li> <li>Talue disclosed on the balance sheet of investments, as well as the fair value of those investments; for securities that are publicly traded, a comparison to publicly- quoted share values where the share price is materially different from fair value.</li> <li>he types and nature of investments, including the amount that is:</li> <li>(1) Publicly traded; and</li> </ul>	Form 10-Q:         Note 7. Loan Servicing         Pillar 3 Regulatory Capital Disclosures:         Equity Securities Not Subject to Market Risk Rule         Form 10-K:         Note 1. Basis of Presentation         Note 18. Fair Value Disclosures         Item 7 - MD&A - Risk Management         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different than the fair values of the investments. Publicly quoted share values are not materially different from the fair values.         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         Form 10-Q:
able 9 Qualita (a) T (a) T (b) V (c) T (d) T	categories of guarantor name.	Form 10-Q:         Note 7. Loan Servicing         Pillar 3 Regulatory Capital Disclosures:         Equity Securities Not Subject to Market Risk Rule         Form 10-K:         Note 1. Basis of Presentation         Note 18. Fair Value Disclosures         Item 7 - MD&A - Risk Management         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different than the fair values of the investments. Publicly quoted share values are not materially different from the fair values.         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different from the fair values.         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         Form 10-Q:         Note 15. Fair Value Disclosures
able 9 Qualita (a) T (a) T (b) V (c) T (d) T (d) T	<ul> <li>- Equities Not Subject to Subpart F of This Part ative: he general qualitative disclosure requirement with respect to equity risk for equities not subject to subpart F of this part, including:</li> <li>(1) Differentiation between holdings on which capital gains are expected and those taken under other objectives including for relationship and strategic reasons; and</li> <li>(2) Discussion of important policies covering the valuation of and accounting for equity holdings not subject to subpart F of this part. This includes the accounting techniques and valuation methodologies used, including key assumptions and practices affecting valuation as well as significant changes in these practices.</li> <li>itative:</li> <li>Yalue disclosed on the balance sheet of investments, as well as the fair value of those investments; for securities that are publicly traded, a comparison to publicly- quoted share values where the share price is materially different from fair value.</li> <li>he types and nature of investments, including the amount that is:</li> <li>(1) Publicly traded; and</li> <li>(2) Non publicly traded.</li> <li>he cumulative realized gains (losses) arising from sales and liquidations in the</li> </ul>	Form 10-Q:         Note 7. Loan Servicing         Pillar 3 Regulatory Capital Disclosures:         Equity Securities Not Subject to Market Risk Rule         Form 10-K:         Note 1. Basis of Presentation         Note 18. Fair Value Disclosures         Item 7 - MD&A - Risk Management         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         The values on the balance sheet are not materially different than the fair values of the investments. Publicly quoted share values are not materially different from the fair values.         Pillar 3 Regulatory Capital Disclosures:         Table 9-1         Form 10-Q:

Disclosure Requirement	Disclosure Location			
(f) Capital requirements categorized by appropriate equity groupings, consistent with the FDIC-supervised institution's methodology, as well as the aggregate amounts and the type of equity investments subject to any supervisory transition regarding regulatory capital requirements.	<i>Pillar 3 Regulatory Capital Disclosures:</i> Table 9-1			
Table 10 - Interest Rate Risk For Non-Trading Activities				
Qualitative:				
(a) The general qualitative disclosure requirement, including the nature of interest rate risk for non-trading activities and key assumptions, including assumptions regarding loan prepayments and behavior of non-maturity deposits, and frequency of measurement of interest rate risk for non-trading activities.	Form 10-K: Item 7 - MD&A - Interest Rate Market Risk (Other than Trading) Item 7 - MD&A - Risk Management Form 10-Q: Item 2 - MD&A - Interest Rate Market Risk (Other than Trading)			
Quantitative:				
(b) The increase (decline) in earnings or economic value (or relevant measure used by management) for upward and downward rate shocks according to management's method for measuring interest rate risk for non-trading activities, categorized by currency (as appropriate).	Form 10-Q: Item 2 - MD&A - Table 17			

## **Forward-Looking Statements**

This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, regarding the financial condition, results of operations, business plans and the future performance of Truist. Words such as "anticipates," "believes," "estimates," "forecasts," "forecasts," "intends," "plans," "projects," "may," "will," "should," "could," and other similar expressions are intended to identify these forward-looking statements.

Forward-looking statements are not based on historical facts but instead represent management's expectations and assumptions regarding Truist's business, the economy, and other future conditions. Such statements involve inherent uncertainties, risks, and changes in circumstances that are difficult to predict. As such, Truist's actual results may differ materially from those contemplated by forward-looking statements. While there can be no assurance that any list of risks and uncertainties or risk factors is complete, important factors that could cause actual results to differ materially from those contemplated by forward-looking statements include the following, without limitation, as well as the risks and uncertainties more fully discussed in Part I, Item 1A-Risk Factors in Truist's Form 10-K for the year ended December 31, 2021:

- residual risks and uncertainties relating to the Merger of heritage BB&T and heritage SunTrust, including the ability to realize the anticipated benefits of the Merger;
- expenses relating to the Merger and application and data center decommissioning;
- deposit attrition, client loss or revenue loss following completed mergers or acquisitions may be greater than anticipated;
- the COVID-19 pandemic disrupted the global economy and adversely impacted Truist's financial condition and results of operations, including through increased expenses, reduced fee income and net interest margin, decreased demand for certain types of loans, and increases in the allowance for credit losses; a resurgence of the pandemic, whether due to new variants of the coronavirus or other factors, could reintroduce or prolong these negative impacts and also adversely affect Truist's capital and liquidity position or cost of capital, impair the ability of borrowers to repay outstanding loans, cause an outflow of deposits, and impair goodwill or other assets;
- Truist is subject to credit risk by lending or committing to lend money, and may have more credit risk and higher credit losses to the extent that loans are concentrated by loan type, industry segment, borrower type or location of the borrower or collateral;
- changes in the interest rate environment, including the replacement of LIBOR as an interest rate benchmark, which could adversely affect Truist's revenue and expenses, the value of assets and obligations, and the availability and cost of capital, cash flows, and liquidity;
- inability to access short-term funding or liquidity, loss of client deposits or changes in Truist's credit ratings, which could increase the cost of funding or limit access to capital markets;
- risk management oversight functions may not identify or address risks adequately, and management may not be able to effectively manage credit risk;
- risks resulting from the extensive use of models in Truist's business, which may impact decisions made by management and regulators;
- failure to execute on strategic or operational plans, including the ability to successfully complete or integrate mergers and acquisitions;
- increased competition, including from (i) new or existing competitors that could have greater financial resources or be subject to different regulatory standards, and (ii)
  products and services offered by non-bank financial technology companies, may reduce Truist's client base, cause Truist to lower prices for its products and services in
  order to maintain market share or otherwise adversely impact Truist's businesses or results of operations;
- failure to maintain or enhance Truist's competitive position with respect to new products, services and technology, whether it fails to anticipate client expectations or because its technological developments fail to perform as desired or do not achieve market acceptance or regulatory approval or for other reasons, may cause Truist to lose market share or incur additional expense;
- negative public opinion, which could damage Truist's reputation;
- increased scrutiny regarding Truist's consumer sales practices, training practices, incentive compensation design, and governance;
- regulatory matters, litigation or other legal actions, which may result in, among other things, costs, fines, penalties, restrictions on Truist's business activities, reputational harm, negative publicity, or other adverse consequences;
- evolving legislative, accounting and regulatory standards, including with respect to climate, capital, and liquidity requirements, and results of regulatory examinations may
  adversely affect Truist's financial condition and results of operations;
- the monetary and fiscal policies of the federal government and its agencies, including in response to rising inflation, could have a material adverse effect on the economy
  and Truist's profitability;
- accounting policies and processes require management to make estimates about matters that are uncertain, including the potential write down to goodwill if there is an
  elongated period of decline in market value for Truist's stock and adverse economic conditions are sustained over a period of time;
- general economic or business conditions, either globally, nationally or regionally, may be less favorable than expected, and instability in global geopolitical matters or volatility in financial markets could result in, among other things, slower deposit or asset growth, a deterioration in credit quality, or a reduced demand for credit, insurance, or other services;
- risks related to originating and selling mortgages, including repurchase and indemnity demands from purchasers related to representations and warranties on loans sold, which could result in an increase in the amount of losses for loan repurchases;
- risks relating to Truist's role as a loan servicer, including an increase in the scope or costs of the services Truist is required to perform, without any corresponding
  increase in servicing fees or a breach of Truist's obligations as servicer;
- Truist's success depends on hiring and retaining key teammates, and if these individuals leave or change roles without effective replacements, Truist's operations and
  integration activities could be adversely impacted, which could be exacerbated in the increased work-from-home environment caused by the COVID-19 pandemic as job
  markets may be less constrained by physical geography;
- · fraud or misconduct by internal or external parties, which Truist may not be able to prevent, detect, or mitigate;
- security risks, including denial of service attacks, hacking, social engineering attacks targeting Truist's teammates and clients, malware intrusion, data corruption
  attempts, system breaches, cyber-attacks, which have increased in frequency with current geopolitical tensions, identity theft, ransomware attacks, and physical security
  risks, such as natural disasters, environmental conditions, and intentional acts of destruction, could result in the disclosure of confidential information, adversely affect
  Truist's business or reputation or create significant legal or financial exposure; and
- widespread outages of operational, communication, or other systems, whether internal or provided by third parties, natural or other disasters (including acts of terrorism and pandemics), and the effects of climate change, including physical risks, such as more frequent and intense weather events, and risks related to the transition to a lower carbon economy, such as regulatory or technological changes or shifts in market dynamics or consumer preferences, could have an adverse effect on Truist's financial condition and results of operations, lead to material disruption of Truist's operations or the ability or willingness of clients to access Truist's products and services.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by applicable law or regulation, Truist undertakes no obligation to revise or update any forward-looking statements.